
Brainsway Ltd. BWAY
$ 19.04
0.11%
Annual report 2024
added 12-27-2025
Brainsway Ltd. Gross Profit 2011-2026 | BWAY
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Brainsway Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.6 M | 23.5 M | 20 M | 23.1 M | 17 M | 18 M | 12.8 M | 8.55 M | 9.1 M | 5.33 M | 2.72 M | 990 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.6 M | 990 K | 14.3 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Burning Rock Biotech Limited
BNR
|
364 M | $ 20.25 | -3.5 % | $ 217 M | ||
|
Co-Diagnostics
CODX
|
2.63 M | $ 5.35 | 5.87 % | $ 157 M | ||
|
Castle Biosciences
CSTL
|
53 M | $ 38.31 | -1.52 % | $ 1.06 B | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
Danaher Corporation
DHR
|
14.2 B | $ 230.53 | 0.7 % | $ 169 B | ||
|
DexCom
DXCM
|
2.29 B | $ 66.36 | -0.02 % | $ 25.6 B | ||
|
BioNano Genomics
BNGO
|
2.77 M | $ 1.56 | 1.96 % | $ 1.98 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
5.98 M | $ 11.2 | -1.58 % | $ 318 M | ||
|
Exact Sciences Corporation
EXAS
|
493 M | $ 101.8 | 0.24 % | $ 18.9 B | ||
|
IQVIA Holdings
IQV
|
3.79 B | $ 225.76 | 0.16 % | $ 40.9 B | ||
|
Fulgent Genetics
FLGT
|
107 M | $ 25.77 | -1.9 % | $ 779 M | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 19.08 | 1.27 % | $ 1.03 B | ||
|
Anixa Biosciences
ANIX
|
83.8 K | $ 3.11 | -0.32 % | $ 99.2 K | ||
|
Myriad Genetics
MYGN
|
585 M | $ 6.23 | 1.22 % | $ 564 M | ||
|
Guardant Health
GH
|
144 M | $ 101.54 | -0.59 % | $ 12.5 B | ||
|
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.21 | -7.06 % | $ 2.26 M | ||
|
NeoGenomics
NEO
|
290 M | $ 11.7 | -0.51 % | $ 1.48 B | ||
|
National Research Corporation
NRC
|
81.5 M | $ 18.42 | -1.86 % | $ 452 M | ||
|
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | ||
|
OPKO Health
OPK
|
219 M | $ 1.32 | 4.37 % | $ 916 M | ||
|
Koninklijke Philips N.V.
PHG
|
7.77 B | $ 27.16 | 0.3 % | $ 20 B | ||
|
Precipio
PRPO
|
6.02 M | $ 23.35 | 1.61 % | $ 30.3 M | ||
|
Personalis
PSNL
|
22.1 M | $ 7.95 | -0.13 % | $ 471 M | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Illumina
ILMN
|
2.86 B | $ 132.66 | 1.14 % | $ 21.1 B | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 200.04 | 0.28 % | $ 10.3 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 172.92 | -0.35 % | $ 19.2 B | ||
|
Biodesix
BDSX
|
18.5 M | $ 6.72 | -1.25 % | $ 871 M | ||
|
Laboratory Corporation of America Holdings
LH
|
3.62 B | $ 251.95 | 0.43 % | $ 21.1 B | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 188.4 | 3.39 % | $ 15.5 B | ||
|
IDEXX Laboratories
IDXX
|
2.38 B | $ 664.7 | -1.75 % | $ 54.8 B | ||
|
Lantheus Holdings
LNTH
|
988 M | $ 67.47 | 1.38 % | $ 4.67 B | ||
|
Mettler-Toledo International
MTD
|
2.33 B | $ 1 406.1 | 0.85 % | $ 29.8 B | ||
|
Agilent Technologies
A
|
2.84 B | $ 137.01 | 0.69 % | $ 41.7 B |